International Journal of Emerging Technologies and Innovative Research (IJETIR)

Impact Factor: 5.731

Volume 5, Issue 12, December 2025

Personalized Drug Therapy Using Artificial Intelligence: A New Frontier in Precision Healthcare

Mrs. Rashmi T V and Mrs. Shilpa Prabhu Patil
Department of Computer Science and Engineering
East Point College of Engineering & Technology, Bengaluru, Karnataka
rashmi.tv@eastpoint.ac.in and shilpa.prapatil@gmail.com

Abstract: *The traditional one-size-fits-all approach in pharmacology often overlooks patient-specific factors such as genetics, lifestyle, and co morbidities—leading to variable drug responses and adverse effects. Artificial Intelligence (AI) is transforming this landscape by enabling personalized drug discovery and therapy optimization. By integrating multi- omics data, electronic health records (EHR), and real-world evidence, AI helps design tailored treatment regimens that maximize efficacy and minimize risk. This paper explores the AI-driven personalization of drug therapy, its underlying technologies, real-world applications, and challenges in implementation. From virtual patient modeling to adaptive dosing strategies, AI is ushering in a new era of precision medicine.*

Keywords: Artificial Intelligence, Personalized Medicine, Drug Optimization, Genomics, Precision Healthcare, Deep Learning, EHR Analytics

I. INTRODUCTION

Despite medical advances, patients often experience varied responses to the same treatment. These disparities arise due to genetic differences, environmental exposures, age, and other variables. Personalized medicine, also known as precision medicine, aims to customize drug therapy for each individual. Artificial Intelligence plays a critical role in realizing this vision. By mining genomics, transcriptomics, proteomics, and EHR data, AI models can predict how specific drugs will interact with an individual's unique biological profile [1][3]. This paper examines the AI tools that are enabling a shift from generalized care to targeted therapeutic interventions— where the right drug, at the right dose, is delivered to the right patient.

II. KEY PHASES IN PERSONALIZED DRUG DISCOVERY

Personalized drug development involves a modified pipeline tailored to individual variability. The key phases are shown in Fig 1.

1. Patient Stratification – Classifying patients based on biomarkers, genotype, and phenotype.
2. Biomarker Discovery – Identifying genetic or molecular signatures associated with drug response.
3. Therapeutic Matching – Using AI to match drugs to patient subgroups with maximum compatibility.
4. Dosing Optimization – Predicting optimal dose levels using reinforcement learning or predictive
5. Response Monitoring – Adaptive algorithms assess real-time data and adjust treatment dynamically [4].

IJETIR
ISSN (Online) 2583-0554
International Journal of Emerging Technologies and Innovative Research (IJETIR)
Impact Factor: 5.731
Volume 5, Issue 12, December 2025

Fig 1: PHASES IN PERSONALIZED DRUG DISCOVERY

III. WHY AI IS ESSENTIAL FOR PERSONALIZED MEDICINE

AI disrupts this conventional pipeline by embedding intelligence at every stage(Fig 2):

• Data Integration: AI can fuse heterogeneous data types—clinical notes, wearable data, omics, imaging, etc.
• Predictive Modeling: Machine learning models forecast drug efficacy, adverse effects, and metabolism [3][6].
• Real-Time Decision Support: NLP and reinforcement learning allow clinicians to adjust therapy on the fly.
• Genomic Interpretation: AI accelerates interpretation of whole-genome data for pharmacogenomics [7].



Fig 2: AI in Drug Personalization

IV. THE AI TOOLS ENABLING

Additional Insights:

• Treatment Recommendation Systems: AI can analyse historical treatment outcomes to suggest optimal therapies for similar patient profiles.

• Drug-Drug Interaction Prediction: AI models help anticipate adverse interactions, particularly in patients on multiple medications.

• Personalized Clinical Trial Matching: AI assists in identifying patients for trials based on molecular and phenotypic data.

• Adaptive Learning Models: AI systems can improve themselves over time using feedback from treatment outcomes, enhancing long-term precision.

• Real-Time Monitoring and Alerts: AI-powered systems can continuously monitor patient vitals and biomarkers via wearable devices and trigger alerts when anomalies are detected, allowing for proactive intervention.

• Digital Twin Modelling: AI can create virtual replicas (digital twins) of patients that simulate how an individual might respond to different drugs or doses, enabling safe and cost-effective personalization before real-world application.

V. THE AI TOOLS ENABLING PERSONALIZATION

AI enables precision drug therapy by offering a range of tools tailored to handle diverse data sources and clinical objectives. The effectiveness of AI in personalized medicine stems from its ability to process and learn from complex, high-dimensional data such as genomic sequences, imaging data, and real-world patient records. Each technique plays a distinct role:The following Table1 highlights how each AI technique contributes to the personalization of drug therapy:

• Machine Learning (ML) helps classify patients into risk groups, predict drug response, and identify responders vs. non-responders.

• Deep Learning (DL) models are particularly powerful for analyzing genomic patterns, medical imaging, and multi-modal data integration.

• Natural Language Processing (NLP) extracts meaningful features from unstructured clinical data such as EHRs, physician notes, and pathology reports.

• Reinforcement Learning (RL) dynamically adjusts treatment recommendations over time, enabling adaptive, personalized care paths.

Table 1: AI TOOLS ENABLING DRUG PERSONALIZATION

Technique	Application	Advantages	Limitations
Machine Learning	Risk stratification, dose prediction	Fast, scalable	Biased training data
Deep Learning	Genomic variant analysis, imaging	Handles complex features	Interpretability
NLP	HER summarization, patient clustering	Real-time text extraction	Domain adaptation challenges
Reinforcement Learning	Dynamic therapy adaptation	Context- aware learning	Requires longitudinal data

VI. CASE STUDIES: AI IN ACTION

A. Deep Genomics

Uses AI to predict how genetic mutations affect RNA splicing and protein function, allowing personalized drug targeting [2].

B. Tempus AI

Analyzes patient records, pathology slides, and genomics to suggest cancer treatment plans tailored to individuals [3].

C. IBM Watson for Oncology

Processes structured and unstructured clinical data to recommend personalized cancer treatments [4]..

D. IDx-DR

FDA-approved AI tool for real-time diabetic retinopathy screening, demonstrating personalization at the point of care [6].

VII. CHALLENGES & CONSIDERATIONS

While AI offers transformative potential, critical challenges remain:

• Privacy & Consent: Personalized medicine requires access to sensitive genomic and health data, which raises significant data ownership and consent concerns [5].

• Bias & Fairness: AI models trained on non- representative or imbalanced datasets may perpetuate or even amplify health disparities among underrepresented populations.

• Interpretability: Many AI models, especially deep learning systems, function as black boxes, making it difficult for clinicians to trust or act on their recommendations [4].

• Regulatory Readiness: There is a lack of standardized frameworks for validating, approving, and monitoring AI-driven personalized therapies.

• Data Interoperability: Patient data often exists in siloed formats across different systems, limiting AI's ability to derive meaningful insights from end- to-end health records.

• Clinical Integration: Integrating AI models into real-world clinical workflows remains complex due to infrastructure gaps and resistance to change among healthcare professionals.

• Cost and Accessibility: High costs associated with sequencing, data storage, and model deployment could make personalized AI-driven treatments less accessible in low-resource settings.

• Model Generalizability: AI models trained in one geographic, ethnic, or clinical context may not perform well when applied to other populations or environments.

VIII. CONCLUSION

AI-driven drug personalization represents the convergence of computation, biology, and clinical care. From decoding patient genomes to guiding real-time interventions, AI has become a foundational tool in precision medicine. While challenges around data quality, ethics, and regulation persist, the momentum toward individualized therapy is undeniable. In the near future, AI will not just support—but define—how personalized medicine is delivered.

REFERENCES

[1] K. Huang et al., “AI-driven Drug Discovery: A Review,” Drug Discovery Today, vol. 27, no. 1, pp. 228–243, 2022.
[2] H. Chen, J. Engkvist, Y. Wang, M. Olivecrona, and T. Blaschke, “The Rise of Deep Learning in Drug Discovery,” Drug Discovery Today, vol. 23, no. 6, pp. 1241–1250, 2018.K. Huang et al., “AI-driven Drug Discovery: A Review,” Drug Discovery Today, vol. 27, no. 1, pp. 228–243, 2022.
[3] M. Zhavoronkov et al., “Deep Learning Enables Rapid Identification of Potential Drug Candidates,” Nature Biotechnology, vol. 38, pp. 1011–1015, 2020.
[4] R. W. Davies, “The Impact of Artificial Intelligence on Clinical Trials,” Frontiers in Medicine, vol. 8, 2021.
[5] L. A. Hendricks et al., “Measuring Ethical Risk in AI Applications in Healthcare,” npj Digital Medicine, vol. 5, no. 1, p. 79, 2022.
[6] E. Beam, “Challenges of AI in Drug Development,” IEEE Transactions on Healthcare Informatics, vol. 9, no. 2, pp. 245–252, 2023.
[7] G. Schneider, “Automating Drug Discovery,” Nature Reviews Drug Discovery, vol. 17, no. 2, pp. 97–113, 2018